论文部分内容阅读
目的:评价奥曲肽与乌司他丁联用对重症急性胰腺炎患者的临床疗效。方法:选取2015年3月—2016年5月期间医院收治的重症急性胰腺炎患者60例,将其随机分为治疗组和常规组(每组30例);常规组患者给予抗感染、胃肠减压与补液预防休克治疗,在此基础上加用奥曲肽治疗,治疗组患者在常规组治疗基础上再加用乌司他丁治疗,比较两组患者治疗后的总有效率、严重并发症的发生率、手术率及病死率,以及尿淀粉酶复常时间、腹痛腹胀缓解时间、平均住院时间。结果:治疗后,治疗组患者总有效率为100.00%高于常规组为80.00%(P<0.05),尿淀粉酶复常时间、腹痛腹胀缓解时间与平均住院时间明显短于常规组(P<0.05)。结论:奥曲肽与乌司他丁联用配合常规治疗重症急性胰腺炎患者的临床疗效优于单用奥曲肽的疗效,能在较短时间内实现更为显著的疗效。
Objective: To evaluate the clinical efficacy of octreotide combined with ulinastatin in patients with severe acute pancreatitis. Methods: Sixty patients with severe acute pancreatitis admitted to our hospital from March 2015 to May 2016 were selected and randomly divided into treatment group and conventional group (30 cases in each group). Patients in routine group were given anti-infective and gastrointestinal Decompression and rehydration prevention of shock treatment, based on the use of octreotide plus treatment group patients in the conventional group based on the treatment plus ulinastatin treatment, the two groups were compared the total effective rate after treatment, severe complications Incidence, operative rate and mortality, as well as urinary amylase normalization time, abdominal pain and abdominal distension time, the average length of stay. Results: After treatment, the total effective rate in the treatment group was 100.00%, which was significantly higher than that in the conventional group (80.00%, P <0.05). The urinary amylase recovery time, abdominal pain and abdominal distention time and hospitalization time were significantly shorter than those in the conventional group (P < 0.05). Conclusion: The clinical efficacy of octreotide combined with ulinastatin in the treatment of severe acute pancreatitis is better than that of octreotide alone, and can achieve more significant effects in a relatively short period of time.